CompletedPhase 2

Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

China126 participantsStarted 2018-09-01

Plain-language summary

To verify the efficacy and safety of endostatin in the treatment of SRILI（symptomatic radiation-induced lung injury） and fibrosis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients defined as NSCLC who could not be operated on, phase III-IV;
✓. EOCG PS: 0-3;
✓. The clinical diagnosis is RILI, with grade 2-3;
✓. No major organ dysfunction, such as heart failure and chronic obstructive pneumonia;
✓. No Endostar use contraindication;
✓. Volunteer to participate, good compliance, can cooperate with the test observation, and sign a written informed consent.

Exclusion criteria

✕. Patient compliance is poor and violates the test regulations;
✕. Major organ dysfunction like liver and kidney occurs, such as myocardial infarction, angina pectoris, liver transaminase increased significantly;
✕. Hemorrhage or thrombus occurs, anticoagulant medication is required;
✕. Serious adverse drug reactions occur during treatment;
✕. The patient asked to be withdrawn from the trial;
✕. Other antiangiogenic drugs were used.

What they're measuring

recrudescence rate of RP（Radiation pneumonitis）

Timeframe: at week12

Trial details

NCT IDNCT03796364

SponsorXinqiao Hospital of Chongqing

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05-31

View on ClinicalTrials.gov More Radiation Pneumonitis trials